Saniona AB
STO:SANION
Saniona AB
Saniona AB engages in the research and development on drugs for diseases of the central nervous system, autoimmune diseases, metabolic diseases, and treatment of pain. The company operates in the area of drugs targeting ion channels to develop therapeutics for pain, central nervous system, and inflammatory or autoimmune diseases. The firm develops a technology platform which enables investigation of all types of ion channel drug targets. Its research is focused on GABAA receptors, nicotinic acetylcholine receptors and potassium channels. The clinical pipeline includes: AN788, a clinical candidate for second line treatment of major depressive disorder (MDD); AN761, to be developed for cognition deficits in schizophrenia and Alzheimer's disease; AN363, a candidate for treatment of pain disorders; and AN346, an anti-inflammatory treatment in inflammatory bowel disease (IBD); as well as several other projects. The firm is engaged in partnerships with Janssen Pharmaceuticals Inc, Pfizer Inc and Atlas Venture Inc.
Saniona AB engages in the research and development on drugs for diseases of the central nervous system, autoimmune diseases, metabolic diseases, and treatment of pain. The company operates in the area of drugs targeting ion channels to develop therapeutics for pain, central nervous system, and inflammatory or autoimmune diseases. The firm develops a technology platform which enables investigation of all types of ion channel drug targets. Its research is focused on GABAA receptors, nicotinic acetylcholine receptors and potassium channels. The clinical pipeline includes: AN788, a clinical candidate for second line treatment of major depressive disorder (MDD); AN761, to be developed for cognition deficits in schizophrenia and Alzheimer's disease; AN363, a candidate for treatment of pain disorders; and AN346, an anti-inflammatory treatment in inflammatory bowel disease (IBD); as well as several other projects. The firm is engaged in partnerships with Janssen Pharmaceuticals Inc, Pfizer Inc and Atlas Venture Inc.
Transformational Year: Saniona saw major progress in 2025, including a key partnership with Jazz Pharmaceuticals and significant organizational growth.
Strong Cash Position: Ended 2025 with SEK 581 million in cash; expects to receive SEK 167 million ($17.5 million) in near-term milestones in 2026.
Clinical Pipeline: Three internal CNS programs are on track to begin Phase I trials around the end of 2026, with data expected in 2027.
Increased Expenses: Operating expenses rose in 2025 and are expected to increase by about 50% in 2026 as the company scales up clinical activity.
Funding Runway: Current cash and expected milestones are projected to fund the company into 2028 and through the planned Phase I trials.
Partnering Strategy: Management remains open to early out-licensing but emphasizes the value potential of advancing programs in-house, particularly SAN2668.
External Validation: Pharmaceutical partnerships and robust interest at industry events highlight growing external interest in Saniona's CNS assets.
